BACKGROUND: : Bullous pemphigoid (BP) is a chronic, autoimmune blistering skin disease that affects patients' daily life and psychosocial well-being. OBJECTIVE: : The aim of the study was to evaluate the quality of life, anxiety, depression and loneliness in BP patients. METHODS: : Fifty-seven BP patients and fifty-seven healthy controls were recruited for the study. The quality of life of each patient was assessed using the Dermatology Life Quality Index (DLQI) scale. Moreover, they were evaluated for anxiety and depression according to the Hospital Anxiety Depression Scale (HADS-scale), while loneliness was measured through the Loneliness Scale-Version 3 (UCLA) scale. RESULTS: : The mean DLQI score was 9.45±3.34. Statistically significant differences on the HADS total scale and in HADS-depression subscale (p=0.015 and p=0.002, respectively) were documented. No statistically significant difference was found between the two groups on the HADS-anxiety subscale. Furthermore, significantly higher scores were recorded on the UCLA Scale compared with healthy volunteers (p=0.003). CONCLUSION: : BP had a significant impact on quality of life and the psychological status of patients, probably due to the appearance of unattractive lesions on the skin, functional problems and disease chronicity.
BACKGROUND: : Bullous pemphigoid (BP) is a chronic, autoimmune blistering skin disease that affects patients' daily life and psychosocial well-being. OBJECTIVE: : The aim of the study was to evaluate the quality of life, anxiety, depression and loneliness in BP patients. METHODS: : Fifty-seven BP patients and fifty-seven healthy controls were recruited for the study. The quality of life of each patient was assessed using the Dermatology Life Quality Index (DLQI) scale. Moreover, they were evaluated for anxiety and depression according to the Hospital Anxiety Depression Scale (HADS-scale), while loneliness was measured through the Loneliness Scale-Version 3 (UCLA) scale. RESULTS: : The mean DLQI score was 9.45±3.34. Statistically significant differences on the HADS total scale and in HADS-depression subscale (p=0.015 and p=0.002, respectively) were documented. No statistically significant difference was found between the two groups on the HADS-anxiety subscale. Furthermore, significantly higher scores were recorded on the UCLA Scale compared with healthy volunteers (p=0.003). CONCLUSION: : BP had a significant impact on quality of life and the psychological status of patients, probably due to the appearance of unattractive lesions on the skin, functional problems and disease chronicity.
Bullous pemphigoid (BP) is a blistering disease of the skin, usually affecting
middle-aged or elderly persons. It is characterized by an intensely pruritic rash,
dominated by tense blisters arising in normal looking or erythematous skin. It may
be localized to one area, or widespread on the trunk and proximal limbs.[1,3] BP is likely to have psychological and social implications for
the patient since it is a chronic condition. Both clinical symptoms and the effects
of treatment can have a strong impact on physical and emotional status.[4,5] They may lead to functional limitations, a need for increased
family support, stress and exclusion from social activities. There are few reports
in the literature regarding BP's impact on patients' quality of life but these are
frequently underestimated by clinicians.[4,6] The aim of the study
was to evaluate the quality of life, anxiety, depression and loneliness in BP
patients.
MATERIALS
We enrolled patients referred to the "Andreas Sygros" Skin Hospital (tertiary
referral center) due to BP. The study protocol was approved by the Ethics Committee
of the "Andreas Sygros" Hospital and written informed consent was obtained from all
patients. The diagnosis was based on clinical and histological grounds. Patients
considered eligible for inclusion were aged over 18 years, able to understand the
Greek language and had not received any treatment during the previous three months.
The study excluded patients with a psychiatric history or a history of psychotropic
drug use.To assess patients' quality of life, the Dermatology Life Quality Index (DLQI) was
used.[7] They were also
evaluated for anxiety and depression, drawing on the Hospital Anxiety and Depression
Scale (HADS), while loneliness was measured by the UCLA loneliness Scale
(UCLA-Version 3).[8,11]The DLQI is a validated, 10-item questionnaire on personal relationships, leisure,
daily activities and treatment. The maximum score is 30, with 0 indicating the least
impairment and 30 the greatest impairment in the patient's quality of
life.[7]The Hospital Anxiety and Depression Scale (HADS) developed by Zigmond and Snaithand
constitutes an instrument for detecting states of anxiety and depression originally
of hospital medical outpatients. It is also appropriate for medical patients in
general, as it does not refer to the somatic symptoms of anxiety and
depression.[8] The HADS is a
self-report rating scale of 14 items designed to measure anxiety and depression, the
emotions that most commonly cause psychological distress in patients (seven items
for each sub-scale). Responses to items are indicated on a four-point Likert Scale,
ranging from 0 to 3 (score range 0-21, for each subscale), where high scores
indicate more symptoms. The authors of the previous study suggested two cut-off
scores for detecting depression and anxiety that have commonly been used in most
studies; scores of 8 to 10 denote doubtful cases, while scores of 11 and above
signify valid cases. HADS has been validated in the Greek population[9]. In this study and in the outpatient
group, HADS values were estimated as follows: total HADS 16.1±7.4,
HADS-Anxiety 8.7±4.3 and HADS-Depression 7.3±3.8; whereas, in the
general population group, they were: 9.1±6.1, 5.1±3.7 and
3.9±3.1, respectively.[9]Additionally, patients were assessed for loneliness according to the UCLA scale
(Version 3). It is a 20-item questionnaire, which measures personal perception of
loneliness and social isolation; higher UCLA scores indicate stronger feelings of
loneliness and isolation. The UCLA scale has also been validated in the Greek
population[11]. In the
general population, UCLA-loneliness scale values were estimated to be
40.08±9.50 for young individuals and 31.51±6.92 for the
elderly[10].The control group was recruited during the same period and included fifty-seven
healthy, age- and sex-matched volunteers from the general population (in our study,
individuals from the administrative staff of the hospital were randomly selected),
with no personal history of BP or any history of psychotropic drug use.
Participation in the control group was voluntary and without financial
compensation.
Statistical analysis
All data were analyzed using the statistical package for social science (SPSS
17.0) for Windows. The t-test was used for quantitative analyses and comparison
of means, the chi-square test was employed for qualitative analyses, while the
Pearson's coefficient correlation (r) was also applied. Results were expressed
as means +/- SD. The statistical significance was determined as a p value of
0.05.
RESULTS
This case-control study included 57 patients, of whom 31 were female and 26 were
male, aged 39-79 (mean 59.73±10.77). The control group consisted of an equal
number of healthy individuals (33 females and 24 males), aged 38-81 (mean
60.66± 11.26). No statistically significant (NS) difference between patients
and controls was documented in terms of age (t=0.45, p>0.05, NS) and sex
(x[2]=0.14, p>0.05,
NS).The DLQI score was 9.45±3.34 in BP patients. Significantly higher scores were
recorded on the UCLA Scale (43.01± 5.66) compared with volunteers
(39.12± 7.79) (p=0.003). Regarding the subscale HADS-depression scores and
HADS-total scale, BP patients had statistically significant higher scores compared
with healthy controls (p=0.002 and p=0.015, respectively). In contrast, no
statistically significant difference was found between the two groups for subscale
HADS-anxiety (Table 1). The duration of
symptoms ranged from three weeks to nine months (average duration was two months). A
positive correlation was noted between loneliness and depression (r=0.216, p=0.021);
and anxiety and depression (r=0.489, p<0.0001). No correlation was noted between
the DLQI scores and anxiety, depression, loneliness or age. Similarly, no
correlation was observed between UCLA scale and age, anxiety, total score of
HADscale and DLQI scores.
Table 1
Anxiety, depression and loneliness in BP patients, quantitatively compared
(t-test) with healthy volunteers
BP Patients (n=57)
Controls (n=57)
t-test
p-value
Total score UCLA scale mean
±SD
43.01±5.66
39.12±7.79
3.05
0.003
Total score HADS-total mean ±SD
13.68±4.07
11.85±3.84
2.45
0.015
Total score HADS-anxiety mean ±SD
5.91±2.30
5.56±2.44
0.788
0.43
Total score HADS-depression mean ±SD
7.77±2.36
6.42±2.09
3.22
0.002
Anxiety, depression and loneliness in BP patients, quantitatively compared
(t-test) with healthy volunteers
DISCUSSION
BP can be a distressing disease and it represents a lifelong burden for affected
patients. Our data showed that the mean DLQI score was 9.45±3.34, confirming
that the condition impairs quality of life. Previous studies evaluating the quality
of life in patients with bullous dermatoses have included smaller groups of BP
patients and demonstrated similar results.[4,5,12,13] Patients
struggle to cope with the disease in everyday life since it affects activities like
walking, carrying and climbing stairs. Specific daily activities such as home
management (problems with work around the house or garden), clothing (having to
change or wash clothes more often) and bathing. can also be complicated. Thus,
patients experience great frustration due to the passive and unfulfilling daily
routine.[14,15]BP's adverse effects on body self-image (feeling unclean and physically
unattractive), the disease's chronic nature and the difficulty in controlling
symptoms may explain the high scores recorded on the HADS-depression scale.
Furthermore, pain, itching and discomfort can have a negative impact on sleep, mood
and enjoyment of life, representing further cause for depression in
patients.[15]The results of the UCLA loneliness scale indicated that personal relationships with
relatives and friends can be also impaired. Skin lesions make them feel disfigured
and repulsive; consequently, patients reduce their social contact. As a result, they
feel lonely and socially isolated. To the best of our knowledge, no previous studies
have evaluated the incidence of depression and loneliness among BP patients.A positive correlation was documented between depression and loneliness in BP
patients. This may be attributable to restrictions on work and daily activities,
patients' concerns over their appearance, the BP treatment and its probable
recurrence. Proper management of depression may help patients to overcome loneliness
and eventually to feel happier and more fulfilled.The main limitation of our study is the relatively low number of patients. However,
this does not detract from the importance of the results. BP had a significant
impact on the quality of life and psychological status of our patients. BP
management focuses mainly on the healing process rather than the patient's emotional
status. Introducing quality of life evaluation into clinical practice could help
clinicians to select patients who would benefit most from the addition of
psychological and social support, offering patients relief from isolation and an
opportunity to share common experiences.
CONCLUSION
Bullous pemphigoid had a significant impact on the quality of life and psychological
status of our patients, probably due to the appearance of unattractive lesions on
the skin, functional problems and disease chronicity.
Authors: C Feliciani; P Joly; M F Jonkman; G Zambruno; D Zillikens; D Ioannides; C Kowalewski; H Jedlickova; S Kárpáti; B Marinovic; D Mimouni; S Uzun; S Yayli; M Hertl; L Borradori Journal: Br J Dermatol Date: 2015-04 Impact factor: 9.302
Authors: Deshan F Sebaratnam; Anna Marie Hanna; Shien-ning Chee; John W Frew; Supriya S Venugopal; Benjamin S Daniel; Linda K Martin; Lesley M Rhodes; Jeremy Choon Kai Tan; Charles Qian Wang; Belinda Welsh; Tamar Nijsten; Dédée F Murrell Journal: JAMA Dermatol Date: 2013-10 Impact factor: 10.282
Authors: Vera Barreto Teixeira; Rita Cabral; Maria Manuel Brites; Ricardo Vieira; Américo Figueiredo Journal: An Bras Dermatol Date: 2014 Mar-Apr Impact factor: 1.896
Authors: Alex M Rokni; Marissa Ayasse; Adnan Ahmed; Lauren Guggina; Robert W Kantor; Jonathan I Silverberg Journal: Arch Dermatol Res Date: 2022-03-09 Impact factor: 3.017
Authors: H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth Journal: J Eur Acad Dermatol Venereol Date: 2021-07-10 Impact factor: 6.166